2024-09-20 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis

This report provides a comprehensive analysis of Vertex Pharmaceuticals Inc. (VRTX) stock, focusing on its performance, technical indicators, and recent financial results.

**1. Performance Comparison:**

VRTX has outperformed the S&P 500 (VOO) by a significant margin. Its cumulative return of 175.99% is 47.00 points higher than the S&P 500's return of 128.99%. This represents a relative outperformance of 78.81% compared to the historical range of VRTX's performance relative to the S&P 500. 

**2. Recent Price Movements:**

* **Closing Price:** $474.16
* **5-day Moving Average:** $481.89
* **20-day Moving Average:** $480.30
* **60-day Moving Average:** $481.91

VRTX's current price is slightly below its recent moving averages, indicating a potential short-term downward trend.

**3. Technical Indicators:**

* **RSI:** 39.91 -  Indicates the stock is currently in oversold territory, suggesting a potential rebound in the near future.
* **PPO:** 0.06 -  Suggests a weak positive momentum, indicating a potential for moderate price increases.
* **Delta_Previous_Relative_Divergence:** -5.43 -  Shows a recent decline in relative outperformance against the S&P 500.
* **Expected_Return:** 17.06% - Represents the potential maximum expected return over the next 5 years based on current investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report for the quarter ended August 2nd, 2024 showed a significant miss compared to analyst expectations. The company reported a loss per share of $13.92, whereas analysts expected a profit of $3.65. Revenue came in at $2.65 billion, slightly lower than expected. This disappointing performance may have contributed to the recent price decline.

**5. Overall Analysis:**

VRTX has consistently outperformed the S&P 500 over the long term. However, recent technical indicators and earnings suggest potential short-term weakness. The stock is currently in oversold territory with weak positive momentum. While the long-term outlook remains positive, investors should closely monitor the company's progress in the coming quarters and its ability to address the recent earnings miss.

**6. Conclusion:**

Vertex Pharmaceuticals Inc. (VRTX) remains a strong company with a promising future in the pharmaceutical industry. Despite recent short-term challenges, its long-term growth potential makes it an attractive investment option. However, investors should exercise caution given the recent price decline and earnings miss. Ongoing monitoring of the company's progress and performance will be crucial for making informed investment decisions. 
